Despite significant advancements in treatment over the past decade, the 5-year survival of multiple myeloma stands at 58% for all SEER stages. We believe that a deeper understanding of both patients and the comparative effectiveness of treatments, alongside novel drugs, is essential for improving outcomes in this complex disease.
Join real-world experts at TriNetX and Databricks as we examine how rich and timely clinical data, unified in a research-ready environment, can provide clinical researchers with the best opportunity to accelerate time-to-insight and influence outcomes.
Agenda:
Multiple Myeloma: Progress Made, Progress Needed
Luis Arthur Flores Pelloso MD, PhD, Executive Medical Director, TA Lead for HemOnc, PPD, part of Thermo Fisher Scientific
Deep Data for a Complex Disease
Jeff Graham, Vice President Real-World Data & Innovation, TriNetX
Scaling Success with the Right Data and Technology
Michael Sanky, Global Industry Lead, Healthcare & Life Sciences, Databricks
During this session, we’ll:
- Explore a recent success in sourcing, curating, and inferring key scores from this data, based on 100,000 de-identified U.S. patients diagnosed since 2010.
- Showcase how organizations can de-identify, gather and harmonize millions of treatment-related observations.
- Demonstrate how to organize data in carefully documented, analysis-ready tables using the power of Databricks Lakehouse.
- Examine how clinical expertise, machine learning experience, and best-in-class technology can converge to better understand disease progression (measured by ECOG scores) for thousands of patients, enabling outcome-oriented evidence generated at scale.
- Present lessons learned applicable to a wide array of clinical data curation and evidence generation projects.
